Every year, ~500 people in every 100,000 are diagnosed with cancer. Of these, 34% will not survive past five years. Cancer resulted in more than 500,000 deaths in 2013 alone . Next generation sequencing has enabled the discovery and characterization of gene-specific mutations that have the potential to be tumorigenic; however, the technology also implicates a large number of genes that are not relevant to an individual’s cancerous state. A shortlist of mutated genes that are relevant to a multitude of cancer types, and that can be expanded to include additional cancer type–specific genes, would be invaluable in clinical and research applications. The Cancer Genome Atlas (TCGA) network performed a systematic analysis of more than 3000 tumors from 12 cancer types to investigate underlying mechanisms of cancer initiation and progression and have identified 127 significantly mutated genes (SMGs) across these tumor types .
The xGen Pan-Cancer Panel is a hybrid capture panel based on the findings of the TCGA network. The panel comprises xGen Lockdown Probes, individually synthesized and quality controlled 120mer oligonucleotides bearing a 5′ biotin modification and manufactured using proprietary Ultramer® synthesis technology.
Panel composition (target genes)